These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 22453096)

  • 1. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.
    Zheng Y; Tesar DB; Benincosa L; Birnböck H; Boswell CA; Bumbaca D; Cowan KJ; Danilenko DM; Daugherty AL; Fielder PJ; Grimm HP; Joshi A; Justies N; Kolaitis G; Lewin-Koh N; Li J; McVay S; O'Mahony J; Otteneder M; Pantze M; Putnam WS; Qiu ZJ; Ruppel J; Singer T; Stauch O; Theil FP; Visich J; Yang J; Ying Y; Khawli LA; Richter WF
    MAbs; 2012; 4(2):243-55. PubMed ID: 22453096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model.
    Falck D; Lechmann M; Momčilović A; Thomann M; Koeleman CAM; Jany C; Malik S; Wuhrer M; Reusch D
    MAbs; 2022; 14(1):2145929. PubMed ID: 36383465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.
    Richter WF; Christianson GJ; Frances N; Grimm HP; Proetzel G; Roopenian DC
    MAbs; 2018 Jul; 10(5):803-813. PubMed ID: 29621428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies.
    Bown HK; Bonn C; Yohe S; Yadav DB; Patapoff TW; Daugherty A; Mrsny RJ
    J Control Release; 2018 Mar; 273():13-20. PubMed ID: 29355621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
    Hu S; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
    Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
    Varkhede N; Forrest ML
    J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans.
    Richter WF; Grimm HP; Gouy MH; Søgaard S; Kreuzer C; Wessels U; Draganov D; Muenzer C; Hoche T
    AAPS J; 2020 Apr; 22(3):63. PubMed ID: 32246215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies Using Human Intravenous Clearance or Antibody Isoelectric Point.
    Zou P
    AAPS J; 2023 Mar; 25(3):31. PubMed ID: 36959523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
    Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
    MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.
    Deng R; Meng YG; Hoyte K; Lutman J; Lu Y; Iyer S; DeForge LE; Theil FP; Fielder PJ; Prabhu S
    MAbs; 2012; 4(1):101-9. PubMed ID: 22327433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.
    Haraya K; Tachibana T; Nezu J
    Xenobiotica; 2017 Mar; 47(3):194-201. PubMed ID: 27151820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies.
    Datta-Mannan A; Estwick S; Zhou C; Choi H; Douglass NE; Witcher DR; Lu J; Beidler C; Millican R
    MAbs; 2020 Jan; 12(1):1770028. PubMed ID: 32486889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
    Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
    Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration.
    Ding N; Yamamoto S; Chisaki I; Nakayama M; Matsumoto SI; Hirabayashi H
    Drug Metab Pharmacokinet; 2021 Dec; 41():100408. PubMed ID: 34710650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    Protein Cell; 2018 Jan; 9(1):15-32. PubMed ID: 28421387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
    Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
    MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.